Back to List View Graph View

Finerenone

Finerenone is a non-steroidal mineralocorticoid receptor antagonist used as a therapy in cardiorenal disease.

Where the papers sit

15 papers from the last 6 months study finerenone directly · updated from PubMed 9 Nov 2026

  • Chronic Kidney Disease

    Kidney research is extending finerenone beyond diabetic nephropathy into non-diabetic CKD and IgA nephropathy. Recurring endpoints include eGFR, proteinuria, serum potassium, and longer-term kidney outcomes, including use alongside SGLT2 inhibitors. Real-world cohorts are testing effectiveness and safety across preserved eGFR and varied treatment histories. Renal protection appears central, but broader disease populations and combination strategies remain under evaluation.

    10 papers · 66.7%

  • Finerenone in Heart Failure

    Heart-failure research is testing finerenone against spironolactone in mildly reduced or preserved ejection fraction. Real-world comparisons focus on 12-month effectiveness and clinical events, including myocardial infarction. Prescribing analyses are mapping uptake across physician specialties and cardiovascular-kidney care. Evidence remains early and comparative rather than establishing superiority.

    3 papers · 20%

  • Cardiac Dysfunction and Injury

    Cardiac studies link finerenone with protection from diabetic cardiomyopathy and microvascular injury. Mechanistic work focuses on endothelial damage, neutrophil extracellular traps, AKT signaling, and cardiac dysfunction. A separate rat study examines finerenone with bosentan in cardiac dysfunction associated with benign prostatic hyperplasia. The shared direction is exploratory cardiovascular protection, but disease contexts and mechanisms remain heterogeneous.

    2 papers · 13.3%

finerenone chemical structure

Papers

The 15 papers from the last 6 months that study finerenone directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Chronic Kidney Disease (10)
  1. PMID 42121102
  2. Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real-World Cohort Study From the FOUNTAIN Platform. Diabetes, obesity & metabolism · 8 Nov 2026 PMID 43000187
  3. Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study. Renal failure · 24 Aug 2026 PMID 42634326
  4. Finerenone for IgA Nephropathy After Renin-Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605541
  5. Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of nephrology · 28 Jul 2026 PMID 42517372
  6. Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study. Clinical medicine (London, England) · 3 Jul 2026 PMID 42398671
  7. Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia. PloS one · 1 Jul 2026 PMID 42384643
  8. Finerenone in Persons with Chronic Kidney Disease without Diabetes. The New England journal of medicine · 5 Jun 2026 PMID 42246672
  9. Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease. Diabetes, obesity & metabolism · 31 May 2026 PMID 42219273
  10. Finerenone Attenuates Peritoneal Fibrosis by Restoring Autophagy Flux. Nephrology (Carlton, Vic.) · 28 May 2026 PMID 42209198
Finerenone in Heart Failure (3)
  1. Finerenone versus spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. ESC heart failure · 30 Sept 2026 PMID 42813221
  2. New Evidence in Heart Failure: 2026 Update. ESC heart failure · 1 Sept 2026 PMID 42679357
  3. Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space. Journal of the American Heart Association · 9 Jun 2026 PMID 42261987
Cardiac Dysfunction and Injury (2)
  1. Finerenone Alleviates Cardiac Microvascular Injury and Neutrophil Extracellular Traps Formation in Diabetic Cardiomyopathy via Regulating AKT1 Phosphorylation. Acta physiologica (Oxford, England) · 29 Aug 2026 PMID 42666003
  2. The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats. Molecular biology reports · 30 Jun 2026 PMID 42377399

By study type

Clinical trials (1)
  1. Finerenone in Persons with Chronic Kidney Disease without Diabetes. The New England journal of medicine · 5 Jun 2026 PMID 42246672
Observational studies and case reports (6)
  1. Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study. Renal failure · 24 Aug 2026 PMID 42634326
  2. Finerenone for IgA Nephropathy After Renin-Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605541
  3. Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of nephrology · 28 Jul 2026 PMID 42517372
  4. Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia. PloS one · 1 Jul 2026 PMID 42384643
  5. Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space. Journal of the American Heart Association · 9 Jun 2026 PMID 42261987
  6. Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease. Diabetes, obesity & metabolism · 31 May 2026 PMID 42219273
Preclinical: animal, cell and lab studies (4)
  1. Finerenone attenuates myocardial fibrosis in myocardial infarction complicated by chronic kidney disease: an integrated study combining network pharmacology, molecular simulations, and in vivo experiments. European journal of pharmacology · 19 Sept 2026 PMID 42762910
  2. Finerenone Alleviates Cardiac Microvascular Injury and Neutrophil Extracellular Traps Formation in Diabetic Cardiomyopathy via Regulating AKT1 Phosphorylation. Acta physiologica (Oxford, England) · 29 Aug 2026 PMID 42666003
  3. The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats. Molecular biology reports · 30 Jun 2026 PMID 42377399
  4. Finerenone Attenuates Peritoneal Fibrosis by Restoring Autophagy Flux. Nephrology (Carlton, Vic.) · 28 May 2026 PMID 42209198
Unclassified: not yet indexed with MeSH (4)
  1. Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real-World Cohort Study From the FOUNTAIN Platform. Diabetes, obesity & metabolism · 8 Nov 2026 PMID 43000187
  2. Finerenone versus spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. ESC heart failure · 30 Sept 2026 PMID 42813221
  3. New Evidence in Heart Failure: 2026 Update. ESC heart failure · 1 Sept 2026 PMID 42679357
  4. Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study. Clinical medicine (London, England) · 3 Jul 2026 PMID 42398671